Zymeworks (Zymeworks) Cash-to-Debt

: 14.01 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zymeworks's cash to debt ratio for the quarter that ended in Dec. 2023 was 14.01.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Zymeworks could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Zymeworks's Cash-to-Debt or its related term are showing as below:

ZYME' s Cash-to-Debt Range Over the Past 10 Years
Min: 7.81 Med: 43.15 Max: 4765.81
Current: 14.01

During the past 10 years, Zymeworks's highest Cash to Debt Ratio was 4765.81. The lowest was 7.81. And the median was 43.15.

ZYME's Cash-to-Debt is ranked better than
60.62% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs ZYME: 14.01

Zymeworks Cash-to-Debt Historical Data

The historical data trend for Zymeworks's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zymeworks Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

43.15

49.32

7.81

17.51

14.01

Zymeworks Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															17.51	12.47	12.48	11.20	14.01

Competitive Comparison

For the Biotechnology subindustry, Zymeworks's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zymeworks Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Zymeworks's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zymeworks's Cash-to-Debt falls into.

Zymeworks Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zymeworks's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	374.327	/	(4.261	+	22.461)
	=	14.01

Zymeworks's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	374.327	/	(4.261	+	22.461)
	=	14.01

Zymeworks (NAS:ZYME) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zymeworks Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zymeworks's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zymeworks (Zymeworks) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zymeworks Inc (NAS:ZYME) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

ZA8:Germany

Address

108 Patriot Drive, Suite A, Middletown, DE, USA, 19709

Website

https://www.zymeworks.com

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Executives

Paul Andrew Moore	officer: Chief Scientific Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Christopher Astle	officer: SVP & Chief Financial Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Kenneth Galbraith	director, officer: Chair & CEO	OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Carlos Campoy	director	11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Miller Derek John Michael	director	108 PATRIOT DRIVE, SUITE A, 1385 WEST 8TH AVENUE, SUITE 540, MIDDLETOWN DE 19709
Neil A Klompas	officer: President & COO	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4
Lota S. Zoth	director	334 CR 692, BUFFALO GAP TX 79508
Troy Cox	director	C/O FOUNDATION MEDICINE, INC., C/O FOUNDATION MEDICINE, INC., 150 SECON, CAMBRIDGE MA 02141
Kenneth J. Hillan	director	C/O ACHAOGEN, INC., 7000 SHORELINE COURT, SUITE 371, SOUTH SAN FRANCISCO CA 94080
Hollings Renton	director
Kelvin Neu	director	860 WASHINGTON STREET, 10TH FLOOR, NEW YORK NY 10014
Natalie Sacks	director	C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Susan Mahony	director	LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Neil Josephson	officer: Chief Medical Officer	114 EAST 4TH AVENUE, SUITE 800, VANCOUVER A1 V5T 1G4